ED50 and ED95 of remifentanil combined with remimazolam in inhibiting tracheal intubation responses in elderly patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500095646

Enrollment

Unknown

Registered

2025-01-09

Start date

2025-01-15

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

remifentanil group:If the previous patient shows a positive response, the dose of remifentanil for the next patient will be increased by 0.1 µg/kg. If the previous patient does not show a positive res

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: Voluntarily sign the informed consent form; Aged >= 60 years; ASA classification I~III; BMI 18.5~27.9 kg/m^2; Scheduled for arterial pressure measurement via puncture; Scheduled for single-lumen tube general anesthesia.

Exclusion criteria

Exclusion criteria: Difficult airway or failure of first attempt at intubation; Currently using benzodiazepines or history of benzodiazepine allergy; Currently using opioids or other analgesics; Poorly controlled hypertension (SBP > 160 mmHg); History of ischemic heart disease; HR < 55 bpm; History of stroke; Severe liver, kidney, or lung diseases.

Design outcomes

Primary

Measure	Time frame
ED50 and ED95 of remifentanil combined with remimazolam in inhibiting tracheal intubation responses in elderly patients;	—

Secondary

Measure	Time frame
Blood pressure;heart rate;Cardiac output;Peripheral vascular resistance;bispectral index;Frequency of vasopressor use;	—

Countries

China

Contacts

Public ContactMa Yue

Qilu Hospital of Shandong University (Qingdao)

supermy0524@163.com+86 185 6181 9588

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026